TFx, which quantify the TFx in circulating system, could serve as a biomarker for patients' tumour burden and could real‐time monitor HCC progression, providing a potential alternative strategy aside from clinically applied biomarker AFP and mRECIST assessment system. The gene discussed is AFP; the disease is neoplasm.